An observational study in Subarachnoid Hemorrhage, sponsored by University of Colorado, Denver. Completed at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by University of Colorado, Denver · Observational
This study evaluates the pharmacokinetic profile of levetiracetam in critically ill patients who have suffered a subarachnoid hemorrhage. The patients will be evaluated for development of augmented renal clearance and the effects and duration of effects this may have on levetiracetam clearance.
521 studies on the registry are indexed under Subarachnoid Hemorrhage; 126 are open to participants now.
This study's enrollment of 15 is below the median of 116 across 234 observational studies indexed under Subarachnoid Hemorrhage.
Browse Subarachnoid Hemorrhage studies →University of Colorado, Denver is the lead sponsor of 1,538 studies on the registry; 319 are open to participants now.
Of its 146 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients who have suffered a non-traumatic subarachnoid hemorrhage requiring strict intake and output monitoring and admission to the neuro-intensive care unit
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Pharmacokinetic modeling
Timed blood draws and urine collections to model drug clearance
Change in systemic levetiracetam clearance over time
calculated systemic levetiracetam clearance (based on plasma concentrations) within 48 hours of initial presentation to the neurointensive care unit and every 5 days thereafter up to 20 days
Time frame: 0-20 days
Change in urinary clearance of levetiracetam and creatinine
12-hour urine collections on day 0, 5, 10, 15, and 20, calculated creatinine based on 12-hour urine collections daily for 7 days following diagnosis of vasospasm, and calculation of direct renal clearance of levetiracitam based on urine collection
Time frame: 0-20 days
Ran from Jan 2016 to primary completion in Jun 2019, 41 months.
Of 116 non-industry observational studies under Subarachnoid Hemorrhage, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 127. This study's 41 months is above that.
Counting every sponsor, half of 119 studies reached it within 37 months; a quarter within 17 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →